Classification, facteurs favorisants, prévention et traitement des effets indésirables (EI) associés au bacille de Calmette-Guérin (BCG) dans le traitement des tumeurs superficielles de vessie

Adaptation of a side‐effect questionnaire for identifying symptoms caused by bacillus Calmette‐Guerin intravesical therapy

“…Within the scope of care of people with NIMBC, there is little evidence on the use of a patient questionnaire to assess treatment side‐effects, due to limited randomized controlled trials 1 and only one validated instrument specific to bladder cancer QoL, published recently by the EORTC 7 . Self‐reported surveys could also be used to assess an individual's susceptibility to adverse effects, to identify patients at risk, and to ensure that preventive measures can be put in place at the earliest opportunity 11 . The main points to consider for the correct administration of intravesical BCG and increase patients' compliance are: 30,31 Accurate communication/education with the patient so they are aware of potential side effects arising when initiating the treatment; Appropriate verbal or written information which should highlight were patients could seek further support (i.e., key contact number, useful websites); Key worker/named nurse that will be responsible for the patient during his BCG treatment. Adequate records and patient support. Correct installation procedure. Early side‐effects diagnosis and treatment through a measurement tool (patient questionnaire). Appropriate early treatment to adverse events. …”

“…A simplified patient questionnaire is considered crucial as part of this process. 11,[19][20][21][22][23] This patient questionnaire must be tailored to each patient population and hospital practice, developed using robust tools (specific to structure and the design of the survey). Finally, they must be reflective of the language used by the local patient group, if they are going to be used in local clinical practice.…”

“…7 Self-reported surveys could also be used to assess an individual's susceptibility to adverse effects, to identify patients at risk, and to ensure that preventive measures can be put in place at the earliest opportunity. 11 The main points to consider for the correct administration of intravesical BCG and increase patients' compliance are: 30,31 • Accurate communication/education with the patient so they are aware of potential side effects arising when initiating the treatment;…”

“…Serious systemic side effects are encountered in less than 5% of patients, but the incidence of these complications increases with the [8][9][10] BCG, bacillus Calmette-Guerin number of instillations performed, 11 often causing delay or interruptions to the instillations, which in turn reduces the efficacy of treatment. 12 Alcorn et al 3 reveal that in several studies, only 16% of the patients with grade 3 NIMBC complete their treatment.…”

“…The four BCG surveys received an overall score: Andius et al17 -16/24, Vahr S. et al1 -14/24, Bohle et al18 -13/24 and Saint et al11 -11/24. The Vahr S. et al1 had the lowest school grade-2 and the Andius et al17 had the highest-4.…”